Clinical trials: Active Ankylosing Spondylitis
Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis
Korean Post-marketing Surveillance for Xeljanz XR
Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea.
- Conditions
- Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
- Trial name
- XRPMS (NCT04876781)
- Testing
- Tofacitinib XR
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Pfizer
Active Ankylosing Spondylitis
Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS
The purpose of this study is to evaluate preliminary efficacy, safety pharmacokinetic (PK) characteristics, pharmacodynamics (PD) haracteristics and immunogenicity of JS005 at different doses in Chinese patients with active…
- Trial name
- NCT05212051
- Testing
- JS005
- Where
- 23 sites in China
- Volunteers
- 131 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Active Ankylosing Spondylitis
Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
- Trial name
- NCT07172360
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Active Ankylosing Spondylitis
Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
- Trial name
- NCT05814939
- Testing
- VC005 tablets, Tofacitinib Citrate Tablets
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Active Ankylosing Spondylitis
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period.
- Trial name
- NCT05407246
- Testing
- Hemay005
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis
Efficacy and Safety Study of SUNPG1622
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
- Trial name
- NCT02980705
- Testing
- SUNPG1622 I dose
- Where
- 4 sites in United States, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Active Sacroiliitis in Ankylosing Spondylitis
Color Doppler Ultrasonography in Evaluation of Active Sacroiliitis in Ankylosing Spondylitis
Evaluate the role of color Doppler ultrasonography (CDUS) in detection of active sacroiliitis in Ankylosing Spondylitis patients using MRI of the sacroiliac joints as a gold standard.
- Trial name
- NCT04329182
- Volunteers
- 40 people
- Sponsor
- Assiut University
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.
Moderate to Severe Active Axial Spondyloarthritis
Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)
Efficacy - To assess efficacy of etanercept versus sulfasalazine when added to NSAIDs in patients with moderate to severe active early axial spondyloarthritis duration of ongoing axial symptoms of less than 5 years.
- Trial name
- NCT00844142
- Testing
- Etanercept 25mg, Sulfasalazine
- Where
- 9 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Charite University, Berlin, Germany